A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
← catalyst calendarNCT06679140 · readout in 409 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
2,330estimated
Sites
252
Countries
Argentina, Belgium, Brazil +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-08 | actual | When the study began enrolling |
| Primary completion | 2027-10-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-02 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID-19 SARS-CoV-2 Infection
Interventions
- Drug: ibuzatrelvir — also filed as PF-07817883
- Drug: placebo
Primary outcome
what the primary-completion date above is the date OFProportion of participants with COVID-19 related emergency department visits, all cause hospitalization and all cause mortality
measured Day 1 through Day 28
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed